Printer Friendly

EntreMed scientists report potent antiangiogenic effects in preclinical studies of recombinant human Endostatin and Angiostatin protein at the American Association for Cancer Research Annual Meeting.

EntreMed, Inc. (Rockville, MD; 301-738-2490) scientists presented several preclinical studies demonstrating the efficacy of Endostatin protein and Angiostatin protein in inhibiting tumor growth this week at the 90th Annual Meeting of the American Association for Cancer Research in Philadelphia, Pennsylvania. EntreMed also reported its manufacturing process for the production of recombinant human (rhu) Endostatin protein yields soluble, well characterized product in quantities sufficient for early clinical trials. In all, thirteen abstracts were presented on Endostatin protein and Angiostatin protein by EntreMed scientists and other researchers from around the world. Endostatin protein and Angiostatin protein are potent, naturally occurring, angiogenesis inhibitors that specifically inhibit endothelial cell proliferation, angiogenesis and tumor growth.

In an American Association for Cancer Research mini-symposium on angiogenesis, EntreMed's vice president for preclinical research, Dr. B. Kim Lee Sim presented an abstract entitled "Potent Inhibition of Experimental Metastases and Primary Tumors by Recombinant Human Endostatin That is Suitable for Human Use." Dr. Sim reported that GMP-Endostatin protein, (clinical grade Endostatin for human use) was manufactured in quantity and shipped to Children's Hospital (Boston, MA) where it was used to treat human prostate cancer xenografts transplanted into mice. The human GMP Endostatin protein had the same activity and efficacy as EntreMed's non-GMP material used in earlier preclinical studies in the United States and Europe, and are the first data confirming the efficacy of EntreMed's clinical grade production in a preclinical model.

In a second EntreMed abstract presented at the American Association for Cancer Research mini-symposium on angiogenesis, entitled "Recombinant Human Angiostatin: Dose-Dependent Inhibition of Early and Late Stage Established Metastases in Mice," EntreMed scientists presented data showing that their recombinant Angiostatin protein markedly inhibited malignant melanoma in both early stage and late stage metastatic cancer in the lungs of mice. EntreMed researchers cloned the human Angiostatin protein and now produce it in scale-up fermentation using the yeast Pichia pastoris.

In total, EntreMed researchers gave nine presentations of the company's own research on its antiangiogenic product candidates and their respective effects in preclinical cancer models at the American Association for Cancer Research Annual Meeting, including two from the company's internal discovery program -- "Enantiomeric, Dependent Antimetastatic Activity of a Stable Thalidomide Analog," and "Tissue Factor Pathway Inhibitor Is an Inhibitor of Angiogenesis." A complete list of EntreMed's scientific study abstracts is attached.

Dr. Joanna C. Horobin, EntreMed's senior vice president of commercial development, commented on the presentations : "EntreMed is pleased to provide progress reports on our antiangiogenic product portfolio at this prestigious scientific meeting. We remain on schedule to commence Phase I safety trials of Endostatin protein later this year."

The American Association for Cancer Research is a professional society with more than 14,000 laboratory and clinical scientists engaged in cancer research in the United States, Canada and 60 other countries. Its principal activities include fostering advances in cancer and biomedical research through programs that promote scientific education and communication, meetings to present significant new discoveries in cancer and the publishing of four major peer-reviewed journals including Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation and Cancer Epidemiology, Biomarkers & Prevention.

EntreMed is a leader in the field of antiangiogenesis research, which studies the inhibition of abnormal blood vessel growth recently associated with a broad range of diseases. The company's strategy is to accelerate development of its core technologies through collaborations and sponsored research programs with university medical departments, research companies and government laboratories.
COPYRIGHT 1999 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Technology Information
Comment:EntreMed scientists report potent antiangiogenic effects in preclinical studies of recombinant human Endostatin and Angiostatin protein at the American Association for Cancer Research Annual Meeting.(Technology Information)
Publication:BIOTECH Patent News
Geographic Code:1USA
Date:Apr 1, 1999
Words:563
Previous Article:AltaRex update-legal proceedings with Biomira.
Next Article:SIBIA Neurosciences announces license of patented transcription based assay technology to SmithKline Beecham.
Topics:


Related Articles
ENTREMED GETS GENE PATENT FOR ANGIOSTATIN PROTEIN
Cell Genesys and EntreMed announce research collaboration for cancer gene therapy.
Binding site for Endostatin protein identified.
Entremed announces cardiovascular research collaboration with Children's Hospital, Boston.
EntreMed Research emphasizing low-dose cancer therapy featured at cancer research meeting.
Entremed files counterclaims against Abbott to protect its rights to kringle 5 discovery as potential cancer treatment.
Entremed reports on tissue factor pathway inhibitor as an antiangiogenic agent.
EntreMed announces gene target delivery licensing deal with Oxford BioMedica.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters